On Jun 27, 2018 Veracyte Inc (NASDAQ:VCYT) Sellers Increased Their Shorts By 3.35%

June 27, 2018 - By Daniel Mitchell

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo

During Q1 2018 the big money sentiment decreased to 1.04. That’s change of 0.19, from 2017Q4’s 1.23. 4 investors sold all, 24 reduced holdings as Veracyte, Inc. ratio dropped. 18 increased holdings while 11 funds took holdings. Funds hold 20.91 million shares thus 2.49% less from 2017Q4’s 21.45 million shares.
Birchview Limited Partnership has 0.43% invested in Veracyte, Inc. (NASDAQ:VCYT). Proshare Advisors Ltd Com holds 0% or 18,883 shs. 55,158 are owned by Bank Of America Corporation De. Legal General Gru Public Llc stated it has 4,853 shs. Schwab Charles Mgmt Incorporated, a California-based fund reported 166,876 shs. Perkins Mgmt Inc holds 19,380 shs or 0.1% of its capital. Renaissance Ltd Llc reported 512,800 shs. Jpmorgan Chase And Company holds 129,266 shs. 21,850 are owned by Blair William & Il. Amer International Gp Inc has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 15,140 shs. Citadel Limited Liability Com owns 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 11,178 shs. Panagora Asset Management has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). First Light Asset Management Ltd Liability Com invested 1.04% of its capital in Veracyte, Inc. (NASDAQ:VCYT). Deutsche National Bank Ag reported 25,416 shs. Moreover, Bnp Paribas Arbitrage has 0% invested in Veracyte, Inc. (NASDAQ:VCYT).

Veracyte, Inc. had 2 sales and 0 buys since June 12, 2018. This’s net activity of $276,513. 20,000 shs were sold by Hall Christopher M, worth $180,464 on Friday, June 15.

Veracyte Inc (NASDAQ:VCYT) had an increase of its shares shorted by 3.35%. It was published in June by FINRA the 836,700 shares shorted on VCYT. That’s 3.35% up from 809,600 shares. Previous VCYT’s position will need 6 days to restore. It has 137,100 average volume. Veracyte Inc float short is 4.01%.

The last price was $9.29.Since June 27, 2017 it’s 6.02% down thus downtrending. VCYT underperformed the S&P 500 by 18.59%.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The firm is worth $319.07 million. The firm uses genomic technology to resolve diagnostic ambiguity.Currently it has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Another two news for Veracyte, Inc. (NASDAQ:VCYT) were recently posted by: Businesswire.com on June 25, 2018 with title “Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year”. The other Globenewswire.com‘s article was titled “New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business …” and posted on June 21, 2018.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: